London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.

Global Dyspnea Treatment MarketThe global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by ...

and Hikma and partner Vectura require a further trial to get their drug past the FDA. A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early ...

Tobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector ... says matches up with its focus on inhalation and aerosolisation devices.

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

But if you try your hand... Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep.